menu
    • menu
    [{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Etokimab","moa":"Interleukin-33","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":1.3400000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":1.3400000000000001,"dosageForm":"","sponsorNew":"AnaptysBio \/ GlaxoSmithKline","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio \/ GlaxoSmithKline"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Tesaro","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.23999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"AnaptysBio \/ TESARO","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio \/ TESARO"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Dostarlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AnaptysBio \/ Sagard Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio \/ Sagard Healthcare"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ANB032","moa":"BTLA","graph1":"Immunology","graph2":"Phase I","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"IL-36","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Niraparib Tosylate","moa":"PARP","graph1":"Oncology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"AnaptysBio \/ DRI Healthcare Trust","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ AnaptysBio","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ AnaptysBio"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rosnilimab","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio \/ GSK"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CBS004","moa":"","graph1":"Immunology","graph2":"IND Enabling","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"AnaptysBio \/ AnaptysBio","highestDevelopmentStatusID":"5","companyTruncated":"AnaptysBio \/ AnaptysBio"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Sagard Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Dostarlimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"AnaptysBio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Sagard Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"AnaptysBio \/ Sagard Healthcare"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Imsidolimab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"AnaptysBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AnaptysBio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AnaptysBio \/ Not Applicable"},{"orgOrder":0,"company":"AnaptysBio","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"ANB032","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AnaptysBio","amount2":0.10000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AnaptysBio \/ TD Cowen","highestDevelopmentStatusID":"14","companyTruncated":"AnaptysBio \/ TD Cowen"}]

    Find Clinical Drug Pipeline Developments & Deals by AnaptysBio

    Menu

    AnaptysBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ANB032

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : TD Cowen

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

                            Details : The net proceeds will be used to fund the clinical development of the company's lead product ANB032 BTLA agonist antibody, which is being evaluated for the treatment of Atopic Dermatitis Eczema.

                            Brand Name : ANB032

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 14, 2024

                            Lead Product(s) : ANB032

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : TD Cowen

                            Deal Size : $100.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Sagard Healthcare

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Anaptys to Receive $50 Million from Amended Agreement with Sagard for Jemperli Royalties

                            Details : Jemperli (dostarlimab) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

                            Brand Name : Jemperli

                            Molecule Type : Large molecule

                            Upfront Cash : $50.0 million

                            May 09, 2024

                            Lead Product(s) : Dostarlimab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Sagard Healthcare

                            Deal Size : $50.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anaptys Reports Positive Results from GEMINI-2 Phase 3 Trial of Imsidolimab in Psoriasis

                            Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.

                            Brand Name : ANB019

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 09, 2024

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBS004

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Recipient : Centessa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio fr...

                            Details : Under the terms of the agreement, Anaptys will receive from Centessa an exclusive, global license for ANB101 (CBS004), a potentially best-in-class BDCA2 modulator antibody that targets pDCs and ANB102, an extended half-life BDCA2 modulator.

                            Brand Name : ANB101

                            Molecule Type : Large molecule

                            Upfront Cash : $10.0 million

                            November 27, 2023

                            Lead Product(s) : CBS004

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Recipient : Centessa Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pust...

                            Details : ANB019 (imsidolimab) is a fully humanized IgG4 antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, that is being developed for the treatment of GPP.

                            Brand Name : ANB019

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 09, 2023

                            Lead Product(s) : Imsidolimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab-gxly,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in ...

                            Details : JEMPERLI (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

                            Brand Name : Jemperli

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 31, 2023

                            Lead Product(s) : Dostarlimab-gxly,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab-gxly,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Anaptys Bio- and GSK-Partnered Immuno-Oncology Agent Jemperli (dostarlimab-gxly) Plus Chemotherapy Demonstrate...

                            Details : Jemperli (dostarlimab-gxly) is a PD-1-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. It is being investigated for mismatch repair-deficient/microsatellite instability-high locally advan...

                            Brand Name : Jemperli

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 27, 2023

                            Lead Product(s) : Dostarlimab-gxly,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

                            Details : ANB030 (Rosnilimab), its investigational wholly owned PD-1 agonist, demonstrates best-in-class activity in vitro with superior inhibition of T cell proliferation, reduction in inflammatory cytokine secretion (Th1, Th2, Th17) and depletion of PD-1+ T cell...

                            Brand Name : ANB030

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : Rosnilimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AnaptysBio- And GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) Meets Primary Endpoint In Phas...

                            Details : JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.

                            Brand Name : Jemperli

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 02, 2022

                            Lead Product(s) : Dostarlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            AnaptysBio

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dostarlimab,Pemetrexed,Cisplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            GSK Announces Positive Headline Results From PERLA, The Phase II Trial Of Jemperli (dostarlimab) Plus Chemothe...

                            Details : Full results from the PERLA phase II trial, including the primary endpoint of ORR and the key secondary endpoint of progression-free survival, with results by programmed death ligand-1 (PD-L1) expression subgroups.

                            Brand Name : Jemperli

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : Dostarlimab,Pemetrexed,Cisplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : GSK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth